依奇珠单抗治疗中重度斑块型银屑病疗效观察

doi:10.20223/j.cnki.1000-8535.2024.10.005

摘要/Abstract

摘要： 目的探讨依奇珠单抗对中重度斑块型银屑病的治疗效果。方法选取厦门大学附属第一医院2022年1月—2023年8月收治的75例中重度斑块型银屑病患者,应用抽签法进行分组,分为试验组（n=35）与对照组（n=40）。对照组采取常规外用药物治疗,试验组采取依奇珠单抗治疗。对比两组临床疗效,治疗前后外周血调节性T细胞（Treg）和辅助性T细胞17（Th17/Treg）细胞水平变化,并对所有患者进行6个月门诊复查随访,对比复发率及不良反应。结果试验组总有效率88.57%,高于对照组的67.50%（χ²=4.730,P=0.028）;治疗后两组患者Treg细胞升高,试验组（5.59±1.24）%高于对照组（4.12±1.13）%,对比差异有统计学意义（t=5.371,P<0.001）,Th17细胞、Th17/Treg细胞降低,试验组[（1.06±0.14）%、0.19±0.05]低于对照组[（1.71±0.28）%、0.42±0.14],对比差异有统计学意义（t=12.434、9.212,P<0.001）;试验组停药后6个月复发率低于对照组（5.71% vs 27.50%,χ²=6.180,P=0.013）;试验组不良反应发生率略高于对照组,组间对比差异无统计学意义（14.29% vs 5.00%,χ²=1.900,P=0.168）。结论依奇珠单抗治疗中重度斑块型银屑病疗效显著,可调节Th17/Treg平衡,降低停药后复发率,且安全性较高。

关键词: 依奇珠单抗, 斑块型银屑病, Th17/Treg, 复发率, 不良反应

Abstract: Objective To explore the therapeutic effect of Ixekizumab on moderate to severe plaque psoriasis. Methods Seventy-five patients with moderate to severe plaque psoriasis who were admitted to the First Affiliated Hospital of Xiamen University from January 2022 to August 2023 were selected and allocated by lottery into an experimental group（n=35）and a control group（n=40）．The control group received routine external medication while the experimental group received Ixekizumab treatment．The clinical efficacy of two groups,changes in Th17/Treg cell values before and after treatment were compared,and a 6-month outpatient follow-up for all patients was conducted to compare recurrence rates and incidence of adverse reactions. Results The total response rate in the experimental group was 88.57%,which was higher than the 67.50% in the control group（χ²=4.730,P=0.028）．After treatment,the level of Treg cell in the two groups was significantly higher,and the level of Treg cell experimental in the group was higher than that in the control group[（5.59±1.24）% vs （4.12±1.13）%,t=5.371,P<0.001]．After treatment,the level of Th17 and Th17/Treg cell in the two groups were lower,and the level of Th17 cell and Th17/Treg in the experimental group[（1.06±0.14）%,0.19±0.05] were significantly lower than those in the control group[（1.71±0.28）%,0.42±0.14],which was statistically significant（t=12.434、9.212,P<0.001）．The relapse rate at 6 months after drug withdrawal in the experimental group was significantly lower than that in the control group（5.71% vs 27.50,χ²=6.180,P=0.013）．The incidence of adverse reactions in the experimental group was higher than that in the control group,but with no statistical significance（14.29% vs 5.00%,χ²=1.900,P=0.168）. Conclusions Ixekizumab has a significant therapeutic effect on moderate to severe plaque psoriasis．It can regulate the Th17/Treg balance and reduce the recurrence rate after discontinuation,and with high safety．

Key words: ixekizumab, plaque psoriasis, Th17/Treg, recurrence rate, adverse reactions

林明慧, 蔡长斌, 林苑云, 张素雅, 陈丽香. 依奇珠单抗治疗中重度斑块型银屑病疗效观察[J]. 广州医药, 2024, 55(10): 1129-1133.

LIN Minghui, CAI Changbin, LIN Yuanyun, ZHANG Suya, CHEN Lixiang. Observation on the therapeutic effect of Ixekizumab in the treatment of moderate to severe plaque psoriasis[J]. Guangzhou Medical Journal, 2024, 55(10): 1129-1133.

参考文献

[1] JIN J Q,ELHAGE K G,SPENCER R K,et al.Mendelian randomization studies in psoriasis and psoriatic arthritis:A systematic review[J].J Invest Dermatol,2023,143(5):762-776.e3.
[2] KO S H,CHI C C,YEH M L,et al.Lifestyle changes for treating psoriasis[J].Cochrane Database Syst Rev,2019,7(7):CD011972.
[3] MASSON REGNAULT M,SHOURICK J,JENDOUBI F,et al.Time to relapse after discontinuing systemic treatment for psoriasis:A systematic review[J].Am J Clin Dermatol,2022,23(4):433-447.
[4] MOINI JAZANI A,AYATI M H,NADIRI A A,et al.Efficacy of hydrotherapy,spa therapy,and balneotherapy for psoriasis and atopic dermatitis:A systematic review[J].Int J Dermatol,2023,62(2):177-189.
[5] KARAMANAKOS A,VERGOU T,PANOPOULOS S,et al.Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy[J].Eur J Dermatol,2021,31(3):307-317.
[6] ALINAGHI F,CALOV M,KRISTENSEN L E,et al.Prevalence of psoriatic arthritis in patients with psoriasis:A systematic review and meta-analysis of observational and clinical studies[J].J Am Acad Dermatol,2019,80(1):251-265.e19.
[7] CARRASQUILLO O Y,PABÓN-CARTAGENA G,FALTO-AIZPURUA L A,et al.Treatment of erythrodermic psoriasis with biologics:A systematic review[J].J Am Acad Dermatol,2020,83(1):151-158.
[8] 叶珍珍,王文慧,郭金竹.斑块状银屑病司库奇尤单抗应答不良转换为依奇珠单抗的疗效及安全性观察[J].中国皮肤性病学杂志,2023,37(6):673-678.
[9] 胡逸飞,吴亚鹃,卢周,等.依奇珠单抗治疗银屑病合并尿毒症1例[J].中国皮肤性病学杂志,2023,37(10):1189-1191.
[10] 朱学骏. 组织病理学在临床皮肤科学中的作用与地位:通过临床学习皮肤组织病理学[C]// 中华中医药学会皮肤科分会学术会议、全国中医药防治皮肤病成果与技术交流大会、全国中西医结合皮肤科治疗新技术临床推广应用高级研修班文献汇编.武汉,2004:9-10.
[11] BERTH-JONES J,GROTZINGER K,RAINVILLE C,等.一项评价银屑病严重程度的3种量表(银屑病面积和严重性指数、医师全面评估指标和点阵系统医师)的评定者之间和之内可靠性的研究[J].世界核心医学期刊文摘(皮肤病学分册),2006(12):12.
[12] WU P C,HUANG I H,WANG C W,et al.New onset and exacerbations of psoriasis following covid-19 vaccines:A systematic review[J].Am J Clin Dermatol,2022,23(6):775-799.
[13] VAENGEBJERG S,SKOV L,EGEBERG A,et al.Prevalence,incidence,and risk of cancer in patients with psoriasis and psoriatic arthritis:A systematic review and meta-analysis[J].JAMA Dermatol,2020,156(4):421-429.
[14] SONG G,YOON H Y,YEE J,et al.Antihypertensive drug use and psoriasis:A systematic review,meta- and network meta-analysis[J].Br J Clin Pharmacol,2022,88(3):933-941.
[15] 张莉,杨琦,李霞,等.依奇珠单抗治疗毛发红糠疹1例[J].中国皮肤性病学杂志,2022,36(1):64-67.
[16] 游紫梦,刘珈言,闫薇.依奇珠单抗持续改善司库奇尤单抗治疗无效难治性红皮病型银屑病1例[J].四川医学,2022,43(6):625-627.
[17] 苗雅楠,陶颖,李影,等.生物制剂治疗中重度斑块状银屑病患者长期有效性的网状Meta分析[J].中国循证医学杂志,2022,22(8):917-925.
[18] 陆明敏,乔丽,白明明,等.寻常型银屑病患者皮肤屏障功能相关指标检测分析[J].中国麻风皮肤病杂志,2022,38(11):797-799.
[19] 杨艳妮,赵子葳,李新华.丝裂原活化蛋白激酶信号通路在寻常型银屑病发病机制中的研究进展[J].实用临床医药杂志,2022,26(18):136-139.
[20] 吴琼,刘业强.司库奇尤单抗及依奇珠单抗治疗中重度斑块型银屑病小样本短期疗效评价[J].中国皮肤性病学杂志,2022,36(1):48-53.
[21] ZENG L,YANG T,YANG K,et al.Curcumin and curcuma longa extract in the treatment of 10 types of autoimmune diseases:A systematic review and meta-analysis of 31 randomized controlled trials[J].Front Immunol,2022(13):896476.
[22] 杨晓姣,周瑾,董艳,等.IL-17A抑制剂司库奇尤单抗和依奇珠单抗致不良反应文献分析[J].中国新药杂志,2022,31(10):1027-1032.
[23] 刘小英,王浩,阳丽,等.司库奇尤单抗和依奇珠单抗的不良反应信号检测研究[J].医药导报,2022,41(4):572-578.